Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5. The original article has been corrected.
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x)
Cetta I.;Filippi M.;
2022-01-01
Abstract
Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5. The original article has been corrected.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
